BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Scammell TE, Winrow CJ. Orexin receptors: pharmacology and therapeutic opportunities. Annu Rev Pharmacol Toxicol 2011;51:243-66. [PMID: 21034217 DOI: 10.1146/annurev-pharmtox-010510-100528] [Cited by in Crossref: 202] [Cited by in F6Publishing: 194] [Article Influence: 18.4] [Reference Citation Analysis]
Number Citing Articles
1 Martin EJ, Hernandez ME, Hayward LF. Blockade of orexin receptors attenuates the cardiovascular response to air-jet stress in spontaneously hypertensive rats. Auton Neurosci 2016;201:8-16. [PMID: 27591948 DOI: 10.1016/j.autneu.2016.08.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
2 Winrow CJ, Renger JJ. Discovery and development of orexin receptor antagonists as therapeutics for insomnia. Br J Pharmacol 2014;171:283-93. [PMID: 23731216 DOI: 10.1111/bph.12261] [Cited by in Crossref: 86] [Cited by in F6Publishing: 88] [Article Influence: 10.8] [Reference Citation Analysis]
3 Kim TK, Han PL. Functional Connectivity of Basolateral Amygdala Neurons Carrying Orexin Receptors and Melanin-concentrating Hormone Receptors in Regulating Sociability and Mood-related Behaviors. Exp Neurobiol 2016;25:307-17. [PMID: 28035181 DOI: 10.5607/en.2016.25.6.307] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
4 Maejima T, Masseck OA, Mark MD, Herlitze S. Modulation of firing and synaptic transmission of serotonergic neurons by intrinsic G protein-coupled receptors and ion channels. Front Integr Neurosci 2013;7:40. [PMID: 23734105 DOI: 10.3389/fnint.2013.00040] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 3.6] [Reference Citation Analysis]
5 Leinninger GM. Lateral thinking about leptin: a review of leptin action via the lateral hypothalamus. Physiol Behav 2011;104:572-81. [PMID: 21550356 DOI: 10.1016/j.physbeh.2011.04.060] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 3.7] [Reference Citation Analysis]
6 Roecker AJ, Mercer SP, Schreier JD, Cox CD, Fraley ME, Steen JT, Lemaire W, Bruno JG, Harrell CM, Garson SL, Gotter AL, Fox SV, Stevens J, Tannenbaum PL, Prueksaritanont T, Cabalu TD, Cui D, Stellabott J, Hartman GD, Young SD, Winrow CJ, Renger JJ, Coleman PJ. Discovery of 5''-chloro-N-[(5,6-dimethoxypyridin-2-yl)methyl]-2,2':5',3''-terpyridine-3'-carboxamide (MK-1064): a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia. ChemMedChem 2014;9:311-22. [PMID: 24376006 DOI: 10.1002/cmdc.201300447] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 5.3] [Reference Citation Analysis]
7 Drake CL, Durrence H, Cheng P, Roth T, Pillai V, Peterson EL, Singh M, Tran KM. Arousability and Fall Risk During Forced Awakenings From Nocturnal Sleep Among Healthy Males Following Administration of Zolpidem 10 mg and Doxepin 6 mg: A Randomized, Placebo-Controlled, Four-Way Crossover Trial. Sleep 2017;40. [PMID: 28575467 DOI: 10.1093/sleep/zsx086] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
8 Perrey DA, German NA, Gilmour BP, Li JX, Harris DL, Thomas BF, Zhang Y. Substituted tetrahydroisoquinolines as selective antagonists for the orexin 1 receptor. J Med Chem 2013;56:6901-16. [PMID: 23941044 DOI: 10.1021/jm400720h] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 3.2] [Reference Citation Analysis]
9 Yurt S, Erman H, Korkmaz GG, Kosar AF, Uysal P, Gelisgen R, Simsek G, Uzun H. The role of feed regulating peptides on weight loss in patients with pulmonary tuberculosis. Clin Biochem 2013;46:40-4. [PMID: 23000316 DOI: 10.1016/j.clinbiochem.2012.09.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
10 Guerreiro S, Florence C, Rousseau E, Hamadat S, Hirsch EC, Michel PP. The Sleep-Modulating Peptide Orexin-B Protects Midbrain Dopamine Neurons from Degeneration, Alone or in Cooperation with Nicotine. Mol Pharmacol 2015;87:525-32. [DOI: 10.1124/mol.114.095703] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
11 Stettner GM, Kubin L. Antagonism of orexin receptors in the posterior hypothalamus reduces hypoglossal and cardiorespiratory excitation from the perifornical hypothalamus. J Appl Physiol (1985) 2013;114:119-30. [PMID: 23104701 DOI: 10.1152/japplphysiol.00965.2012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
12 Arrigoni E, Chee MJS, Fuller PM. To eat or to sleep: That is a lateral hypothalamic question. Neuropharmacology 2019;154:34-49. [PMID: 30503993 DOI: 10.1016/j.neuropharm.2018.11.017] [Cited by in Crossref: 49] [Cited by in F6Publishing: 39] [Article Influence: 12.3] [Reference Citation Analysis]
13 Mahler SV, Smith RJ, Moorman DE, Sartor GC, Aston-Jones G. Multiple roles for orexin/hypocretin in addiction. Prog Brain Res 2012;198:79-121. [PMID: 22813971 DOI: 10.1016/B978-0-444-59489-1.00007-0] [Cited by in Crossref: 140] [Cited by in F6Publishing: 76] [Article Influence: 14.0] [Reference Citation Analysis]
14 Hoffmann J, Supronsinchai W, Akerman S, Andreou AP, Winrow CJ, Renger J, Hargreaves R, Goadsby PJ. Evidence for orexinergic mechanisms in migraine. Neurobiology of Disease 2015;74:137-43. [DOI: 10.1016/j.nbd.2014.10.022] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 7.1] [Reference Citation Analysis]
15 Jacobson LH, Chen S, Mir S, Hoyer D. Orexin OX2 Receptor Antagonists as Sleep Aids. In: Lawrence AJ, de Lecea L, editors. Behavioral Neuroscience of Orexin/Hypocretin. Cham: Springer International Publishing; 2017. pp. 105-36. [DOI: 10.1007/7854_2016_47] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
16 Leonard CS, Ishibashi M. Orexin Receptor Functions in the Ascending Arousal System. In: Sakurai T, Pandi-perumal S, Monti JM, editors. Orexin and Sleep. Cham: Springer International Publishing; 2015. pp. 67-80. [DOI: 10.1007/978-3-319-23078-8_5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
17 Heifetz A, Morris GB, Biggin PC, Barker O, Fryatt T, Bentley J, Hallett D, Manikowski D, Pal S, Reifegerste R, Slack M, Law R. Study of Human Orexin-1 and -2 G-Protein-Coupled Receptors with Novel and Published Antagonists by Modeling, Molecular Dynamics Simulations, and Site-Directed Mutagenesis. Biochemistry 2012;51:3178-97. [DOI: 10.1021/bi300136h] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
18 Levanti M, Germanà A, Abbate F. Orexin A expression in the ovary of dog and cat. Reprod Domest Anim 2015;50:247-50. [PMID: 25601132 DOI: 10.1111/rda.12478] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
19 Uslaner JM, Tye SJ, Eddins DM, Wang X, Fox SV, Savitz AT, Binns J, Cannon CE, Garson SL, Yao L, Hodgson R, Stevens J, Bowlby MR, Tannenbaum PL, Brunner J, Mcdonald TP, Gotter AL, Kuduk SD, Coleman PJ, Winrow CJ, Renger JJ. Orexin receptor antagonists differ from standard sleep drugs by promoting sleep at doses that do not disrupt cognition. Sci Transl Med 2013;5:179ra44. [PMID: 23552372 DOI: 10.1126/scitranslmed.3005213] [Cited by in Crossref: 66] [Cited by in F6Publishing: 63] [Article Influence: 7.3] [Reference Citation Analysis]
20 Tsuchimine S, Hattori K, Ota M, Hidese S, Teraishi T, Sasayama D, Hori H, Noda T, Yoshida S, Yoshida F, Kunugi H. Reduced plasma orexin-A levels in patients with bipolar disorder. Neuropsychiatr Dis Treat 2019;15:2221-30. [PMID: 31496705 DOI: 10.2147/NDT.S209023] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
21 Yeoh JW, Campbell EJ, James MH, Graham BA, Dayas CV. Orexin antagonists for neuropsychiatric disease: progress and potential pitfalls. Front Neurosci 2014;8:36. [PMID: 24616658 DOI: 10.3389/fnins.2014.00036] [Cited by in Crossref: 59] [Cited by in F6Publishing: 59] [Article Influence: 7.4] [Reference Citation Analysis]
22 Heifetz A, Barker O, Morris GB, Law RJ, Slack M, Biggin PC. Toward an understanding of agonist binding to human Orexin-1 and Orexin-2 receptors with G-protein-coupled receptor modeling and site-directed mutagenesis. Biochemistry 2013;52:8246-60. [PMID: 24144388 DOI: 10.1021/bi401119m] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
23 Campbell EJ, Marchant NJ, Lawrence AJ. A sleeping giant: Suvorexant for the treatment of alcohol use disorder? Brain Res 2020;1731:145902. [PMID: 30081035 DOI: 10.1016/j.brainres.2018.08.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
24 Grasselli F, Bussolati S, Grolli S, Di Lecce R, Dall'Aglio C, Basini G. Effects of Orexin B on Swine Granulosa and Endothelial Cells. Animals (Basel) 2021;11:1812. [PMID: 34204547 DOI: 10.3390/ani11061812] [Reference Citation Analysis]
25 Jalewa J, Wong-lin K, Mcginnity TM, Prasad G, Hölscher C. Increased number of orexin/hypocretin neurons with high and prolonged external stress-induced depression. Behavioural Brain Research 2014;272:196-204. [DOI: 10.1016/j.bbr.2014.05.030] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 5.1] [Reference Citation Analysis]
26 Courault P, Demarquay G, Zimmer L, Lancelot S. Cluster headache: state of the art of pharmacological treatments and therapeutic perspectives. Fundam Clin Pharmacol 2021;35:595-619. [DOI: 10.1111/fcp.12636] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
27 Pace M, Adamantidis A, Facchin L, Bassetti C. Role of REM Sleep, Melanin Concentrating Hormone and Orexin/Hypocretin Systems in the Sleep Deprivation Pre-Ischemia. PLoS One 2017;12:e0168430. [PMID: 28061506 DOI: 10.1371/journal.pone.0168430] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 3.4] [Reference Citation Analysis]
28 Gotter AL, Garson SL, Stevens J, Munden RL, Fox SV, Tannenbaum PL, Yao L, Kuduk SD, McDonald T, Uslaner JM, Tye SJ, Coleman PJ, Winrow CJ, Renger JJ. Differential sleep-promoting effects of dual orexin receptor antagonists and GABAA receptor modulators. BMC Neurosci 2014;15:109. [PMID: 25242351 DOI: 10.1186/1471-2202-15-109] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
29 Jacobson LH, Callander GE, Hoyer D. Suvorexant for the treatment of insomnia. Expert Rev Clin Pharmacol 2014;7:711-30. [PMID: 25318834 DOI: 10.1586/17512433.2014.966813] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
30 Szabadi E. GHB for cataplexy: Possible mode of action. J Psychopharmacol 2015;29:744-9. [DOI: 10.1177/0269881115573807] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
31 Nixon JP, Kotz CM, Novak CM, Billington CJ, Teske JA. Neuropeptides controlling energy balance: orexins and neuromedins. Handb Exp Pharmacol 2012;:77-109. [PMID: 22249811 DOI: 10.1007/978-3-642-24716-3_4] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
32 Lesiak L, Zhou X, Fang Y, Zhao J, Beck JR, Stains CI. Imaging GPCR internalization using near-infrared Nebraska red-based reagents. Org Biomol Chem 2020;18:2459-67. [PMID: 32167123 DOI: 10.1039/d0ob00043d] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
33 España RA, Scammell TE. Sleep neurobiology from a clinical perspective. Sleep 2011;34:845-58. [PMID: 21731134 DOI: 10.5665/SLEEP.1112] [Cited by in Crossref: 81] [Cited by in F6Publishing: 63] [Article Influence: 7.4] [Reference Citation Analysis]
34 Landry I, Nakai K, Ferry J, Aluri J, Hall N, Lalovic B, Moline ML. Pharmacokinetics, Pharmacodynamics, and Safety of the Dual Orexin Receptor Antagonist Lemborexant: Findings From Single-Dose and Multiple-Ascending-Dose Phase 1 Studies in Healthy Adults. Clin Pharmacol Drug Dev 2021;10:153-65. [PMID: 32468649 DOI: 10.1002/cpdd.817] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
35 Chang X, Suo L, Xu N, Zhao Y. Orexin-A Stimulates Insulin Secretion Through the Activation of the OX1 Receptor and Mammalian Target of Rapamycin in Rat Insulinoma Cells. Pancreas 2019;48:568-73. [PMID: 30946236 DOI: 10.1097/MPA.0000000000001280] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
36 Suno R, Kimura KT, Nakane T, Yamashita K, Wang J, Fujiwara T, Yamanaka Y, Im D, Horita S, Tsujimoto H, Tawaramoto MS, Hirokawa T, Nango E, Tono K, Kameshima T, Hatsui T, Joti Y, Yabashi M, Shimamoto K, Yamamoto M, Rosenbaum DM, Iwata S, Shimamura T, Kobayashi T. Crystal Structures of Human Orexin 2 Receptor Bound to the Subtype-Selective Antagonist EMPA. Structure 2018;26:7-19.e5. [DOI: 10.1016/j.str.2017.11.005] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 9.5] [Reference Citation Analysis]
37 Hoyer D, Jacobson LH. Orexin Receptor Antagonists. Curr Sleep Medicine Rep 2017;3:342-53. [DOI: 10.1007/s40675-017-0099-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
38 Cole S, Keefer SE, Anderson LC, Petrovich GD. Medial Prefrontal Cortex Neural Plasticity, Orexin Receptor 1 Signaling, and Connectivity with the Lateral Hypothalamus Are Necessary in Cue-Potentiated Feeding. J Neurosci 2020;40:1744-55. [PMID: 31953368 DOI: 10.1523/JNEUROSCI.1803-19.2020] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 7.5] [Reference Citation Analysis]
39 Vigil JM, Stith SS, Diviant JP, Brockelman F, Keeling K, Hall B. Effectiveness of Raw, Natural Medical Cannabis Flower for Treating Insomnia under Naturalistic Conditions. Medicines (Basel) 2018;5:E75. [PMID: 29997343 DOI: 10.3390/medicines5030075] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
40 Thiyagarajah MT, Herrmann N, Ruthirakuhan M, Li A, Lanctôt KL. Novel Pharmacologic Strategies for Treating Behavioral Disturbances in Alzheimer’s Disease. Curr Behav Neurosci Rep 2019;6:72-87. [DOI: 10.1007/s40473-019-00181-6] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
41 Khodabande F, Akbari E, Ardeshiri MR. The modulation of the spatial reference memory by the orexinergic system of the dorsal raphe nucleus. Life Sci 2021;265:118777. [PMID: 33220293 DOI: 10.1016/j.lfs.2020.118777] [Reference Citation Analysis]
42 Dingemanse J, Hoever P. Absence of pharmacokinetic and pharmacodynamic interactions between almorexant and warfarin in healthy subjects. Drugs R D 2013;13:145-51. [PMID: 23737453 DOI: 10.1007/s40268-013-0017-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
43 Ramirez AD, Gotter AL, Fox SV, Tannenbaum PL, Yao L, Tye SJ, McDonald T, Brunner J, Garson SL, Reiss DR, Kuduk SD, Coleman PJ, Uslaner JM, Hodgson R, Browne SE, Renger JJ, Winrow CJ. Dual orexin receptor antagonists show distinct effects on locomotor performance, ethanol interaction and sleep architecture relative to gamma-aminobutyric acid-A receptor modulators. Front Neurosci 2013;7:254. [PMID: 24399926 DOI: 10.3389/fnins.2013.00254] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
44 Sullivan S. Update on emerging drugs for insomnia. Expert Opinion on Emerging Drugs 2012;17:295-8. [DOI: 10.1517/14728214.2012.693158] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
45 Mediavilla C. Bidirectional gut-brain communication: A role for orexin-A. Neurochem Int 2020;141:104882. [PMID: 33068686 DOI: 10.1016/j.neuint.2020.104882] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
46 Laburthe M, Voisin T. The orexin receptor OX(1)R in colon cancer: a promising therapeutic target and a new paradigm in G protein-coupled receptor signalling through ITIMs. Br J Pharmacol 2012;165:1678-87. [PMID: 21627633 DOI: 10.1111/j.1476-5381.2011.01510.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
47 Janockova J, Dolezal R, Nepovimova E, Kobrlova T, Benkova M, Kuca K, Konecny J, Mezeiova E, Melikova M, Hepnarova V, Ring A, Soukup O, Korabecny J. Investigation of New Orexin 2 Receptor Modulators Using In Silico and In Vitro Methods. Molecules 2018;23:E2926. [PMID: 30423961 DOI: 10.3390/molecules23112926] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
48 Belle MD, Hughes AT, Bechtold DA, Cunningham P, Pierucci M, Burdakov D, Piggins HD. Acute suppressive and long-term phase modulation actions of orexin on the mammalian circadian clock. J Neurosci 2014;34:3607-21. [PMID: 24599460 DOI: 10.1523/JNEUROSCI.3388-13.2014] [Cited by in Crossref: 81] [Cited by in F6Publishing: 34] [Article Influence: 10.1] [Reference Citation Analysis]
49 Yadav A, Yadav SS, Singh S, Dabur R. Natural products: Potential therapeutic agents to prevent skeletal muscle atrophy. Eur J Pharmacol 2022;:174995. [PMID: 35523319 DOI: 10.1016/j.ejphar.2022.174995] [Reference Citation Analysis]
50 Elam HB, Perez SM, Donegan JJ, Lodge DJ. Orexin receptor antagonists reverse aberrant dopamine neuron activity and related behaviors in a rodent model of stress-induced psychosis. Transl Psychiatry 2021;11:114. [PMID: 33558469 DOI: 10.1038/s41398-021-01235-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Fadel JR, Jolivalt CG, Reagan LP. Food for thought: the role of appetitive peptides in age-related cognitive decline. Ageing Res Rev 2013;12:764-76. [PMID: 23416469 DOI: 10.1016/j.arr.2013.01.009] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 5.0] [Reference Citation Analysis]
52 Bettica P, Squassante L, Groeger JA, Gennery B, Winsky-Sommerer R, Dijk DJ. Differential effects of a dual orexin receptor antagonist (SB-649868) and zolpidem on sleep initiation and consolidation, SWS, REM sleep, and EEG power spectra in a model of situational insomnia. Neuropsychopharmacology 2012;37:1224-33. [PMID: 22237311 DOI: 10.1038/npp.2011.310] [Cited by in Crossref: 59] [Cited by in F6Publishing: 59] [Article Influence: 5.9] [Reference Citation Analysis]
53 Perrey DA, German NA, Decker AM, Thorn D, Li JX, Gilmour BP, Thomas BF, Harris DL, Runyon SP, Zhang Y. Effect of 1-substitution on tetrahydroisoquinolines as selective antagonists for the orexin-1 receptor. ACS Chem Neurosci 2015;6:599-614. [PMID: 25643283 DOI: 10.1021/cn500330v] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
54 Lee J, Raycraft L, Johnson AW. The dynamic regulation of appetitive behavior through lateral hypothalamic orexin and melanin concentrating hormone expressing cells. Physiol Behav 2021;229:113234. [PMID: 33130035 DOI: 10.1016/j.physbeh.2020.113234] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
55 Subramanian S, Ravichandran M. Orexin receptors: Targets and applications. Fundam Clin Pharmacol 2021. [PMID: 34464995 DOI: 10.1111/fcp.12723] [Reference Citation Analysis]
56 Lammers GJ. Intranasal hypocretin-1: making sense of scents? Sleep Med 2011;12:939-40. [PMID: 22136855 DOI: 10.1016/j.sleep.2011.11.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
57 Callander GE, Olorunda M, Monna D, Schuepbach E, Langenegger D, Betschart C, Hintermann S, Behnke D, Cotesta S, Fendt M, Laue G, Ofner S, Briard E, Gee CE, Jacobson LH, Hoyer D. Kinetic properties of "dual" orexin receptor antagonists at OX1R and OX2R orexin receptors. Front Neurosci 2013;7:230. [PMID: 24376396 DOI: 10.3389/fnins.2013.00230] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
58 Leinninger GM, Opland DM, Jo YH, Faouzi M, Christensen L, Cappellucci LA, Rhodes CJ, Gnegy ME, Becker JB, Pothos EN, Seasholtz AF, Thompson RC, Myers MG Jr. Leptin action via neurotensin neurons controls orexin, the mesolimbic dopamine system and energy balance. Cell Metab 2011;14:313-23. [PMID: 21907138 DOI: 10.1016/j.cmet.2011.06.016] [Cited by in Crossref: 220] [Cited by in F6Publishing: 214] [Article Influence: 22.0] [Reference Citation Analysis]
59 Born S, Gauvin DV, Mukherjee S, Briscoe R. Preclinical assessment of the abuse potential of the orexin receptor antagonist, suvorexant. Regul Toxicol Pharmacol 2017;86:181-92. [PMID: 28279667 DOI: 10.1016/j.yrtph.2017.03.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
60 Nevárez N, de Lecea L. Recent advances in understanding the roles of hypocretin/orexin in arousal, affect, and motivation. F1000Res 2018;7:F1000 Faculty Rev-1421. [PMID: 30254737 DOI: 10.12688/f1000research.15097.1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
61 Merlo Pich E, Melotto S. Orexin 1 receptor antagonists in compulsive behavior and anxiety: possible therapeutic use. Front Neurosci 2014;8:26. [PMID: 24592206 DOI: 10.3389/fnins.2014.00026] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 3.8] [Reference Citation Analysis]
62 Kubin L. Neural Control of the Upper Airway: Respiratory and State-Dependent Mechanisms. Compr Physiol 2016;6:1801-50. [PMID: 27783860 DOI: 10.1002/cphy.c160002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
63 Gao XB. Plasticity in neurons synthesizing wake/arousal promoting hormone hypocretin/orexin. Vitam Horm 2012;89:35-59. [PMID: 22640607 DOI: 10.1016/B978-0-12-394623-2.00003-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
64 Zielinski MR, McKenna JT, McCarley RW. Functions and Mechanisms of Sleep. AIMS Neurosci 2016;3:67-104. [PMID: 28413828 DOI: 10.3934/Neuroscience.2016.1.67] [Cited by in Crossref: 41] [Cited by in F6Publishing: 16] [Article Influence: 6.8] [Reference Citation Analysis]
65 Doghramji PP. Integrating Modern Concepts of Insomnia and its Contemporary Treatment into Primary Care. Postgraduate Medicine 2015;126:82-101. [DOI: 10.3810/pgm.2014.09.2802] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
66 Hoffmann J, May A. Diagnosis, pathophysiology, and management of cluster headache. Lancet Neurol. 2018;17:75-83. [PMID: 29174963 DOI: 10.1016/s1474-4422(17)30405-2] [Cited by in Crossref: 106] [Cited by in F6Publishing: 32] [Article Influence: 21.2] [Reference Citation Analysis]
67 Betschart C, Hintermann S, Behnke D, Cotesta S, Fendt M, Gee CE, Jacobson LH, Laue G, Ofner S, Chaudhari V, Badiger S, Pandit C, Wagner J, Hoyer D. Identification of a novel series of orexin receptor antagonists with a distinct effect on sleep architecture for the treatment of insomnia. J Med Chem 2013;56:7590-607. [PMID: 23964859 DOI: 10.1021/jm4007627] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 6.9] [Reference Citation Analysis]
68 Xu TR, Ward RJ, Pediani JD, Milligan G. Intramolecular fluorescence resonance energy transfer (FRET) sensors of the orexin OX1 and OX2 receptors identify slow kinetics of agonist activation. J Biol Chem 2012;287:14937-49. [PMID: 22389503 DOI: 10.1074/jbc.M111.334300] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
69 Perrey DA, Decker AM, Zhang Y. Synthesis and Evaluation of Orexin-1 Receptor Antagonists with Improved Solubility and CNS Permeability. ACS Chem Neurosci 2018;9:587-602. [PMID: 29129052 DOI: 10.1021/acschemneuro.7b00402] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
70 Fan Y, Jiang E, Gao H, Bigalke J, Chen B, Yu C, Chen Q, Shan Z. Activation of Orexin System Stimulates CaMKII Expression. Front Physiol 2021;12:698185. [PMID: 34276418 DOI: 10.3389/fphys.2021.698185] [Reference Citation Analysis]
71 Jalewa J, Joshi A, McGinnity TM, Prasad G, Wong-Lin K, Hölscher C. Neural circuit interactions between the dorsal raphe nucleus and the lateral hypothalamus: an experimental and computational study. PLoS One 2014;9:e88003. [PMID: 24516577 DOI: 10.1371/journal.pone.0088003] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
72 Sun H, Palcza J, Rosenberg R, Kryger M, Siringhaus T, Rowe J, Lines C, Wagner JA, Troyer MD. Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease. Respir Med 2015;109:416-26. [PMID: 25661282 DOI: 10.1016/j.rmed.2014.12.010] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 4.4] [Reference Citation Analysis]
73 Jupp B, Krivdic B, Krstew E, Lawrence AJ. The orexin1 receptor antagonist SB-334867 dissociates the motivational properties of alcohol and sucrose in rats. Brain Research 2011;1391:54-9. [DOI: 10.1016/j.brainres.2011.03.045] [Cited by in Crossref: 92] [Cited by in F6Publishing: 93] [Article Influence: 8.4] [Reference Citation Analysis]
74 Martin-Fardon R, Boutrel B. Orexin/hypocretin (Orx/Hcrt) transmission and drug-seeking behavior: is the paraventricular nucleus of the thalamus (PVT) part of the drug seeking circuitry? Front Behav Neurosci 2012;6:75. [PMID: 23162448 DOI: 10.3389/fnbeh.2012.00075] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 5.3] [Reference Citation Analysis]
75 Zhang G, Wu XH, Xu GZ, Weng SJ, Yang XL, Zhong YM. Orexin-B modulates synaptic transmission of rod bipolar cells in rat retina. Neuropharmacology 2018;133:38-50. [PMID: 29325900 DOI: 10.1016/j.neuropharm.2018.01.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
76 Calva CB, Fayyaz H, Fadel JR. Effects of Intranasal Orexin-A (Hypocretin-1) Administration on Neuronal Activation, Neurochemistry, and Attention in Aged Rats. Front Aging Neurosci 2019;11:362. [PMID: 32038222 DOI: 10.3389/fnagi.2019.00362] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
77 Abad VC, Guilleminault C. Pharmacological treatment of sleep disorders and its relationship with neuroplasticity. Curr Top Behav Neurosci 2015;25:503-53. [PMID: 25585962 DOI: 10.1007/7854_2014_365] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
78 Socała K, Szuster-ciesielska A, Wlaź P. SB 334867, a selective orexin receptor type 1 antagonist, elevates seizure threshold in mice. Life Sciences 2016;150:81-8. [DOI: 10.1016/j.lfs.2016.02.075] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
79 Zhou L, Smith RJ, Do PH, Aston-Jones G, See RE. Repeated orexin 1 receptor antagonism effects on cocaine seeking in rats. Neuropharmacology 2012;63:1201-7. [PMID: 22971541 DOI: 10.1016/j.neuropharm.2012.07.044] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
80 Ch’ng SS, Lawrence AJ. Distribution of the orexin-1 receptor (OX1R) in the mouse forebrain and rostral brainstem: A characterisation of OX1R-eGFP mice. Journal of Chemical Neuroanatomy 2015;66-67:1-9. [DOI: 10.1016/j.jchemneu.2015.03.002] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 5.0] [Reference Citation Analysis]
81 Steiner MA, Lecourt H, Jenck F. The dual orexin receptor antagonist almorexant, alone and in combination with morphine, cocaine and amphetamine, on conditioned place preference and locomotor sensitization in the rat. Int J Neuropsychopharmacol 2013;16:417-32. [PMID: 22436395 DOI: 10.1017/S1461145712000193] [Cited by in Crossref: 32] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
82 Manteniotis S, Lehmann R, Flegel C, Vogel F, Hofreuter A, Schreiner BS, Altmüller J, Becker C, Schöbel N, Hatt H, Gisselmann G. Comprehensive RNA-Seq expression analysis of sensory ganglia with a focus on ion channels and GPCRs in Trigeminal ganglia. PLoS One 2013;8:e79523. [PMID: 24260241 DOI: 10.1371/journal.pone.0079523] [Cited by in Crossref: 74] [Cited by in F6Publishing: 77] [Article Influence: 8.2] [Reference Citation Analysis]
83 Gamble MC, Katsuki F, McCoy JG, Strecker RE, McKenna JT. The Dual Orexin Receptor Antagonist DORA-22 Improves Mild Stress-induced Sleep Disruption During the Natural Sleep Phase of Nocturnal Rats. Neuroscience 2021;463:30-44. [PMID: 33737028 DOI: 10.1016/j.neuroscience.2021.03.003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
84 Beig MI, Dampney BW, Carrive P. Both Ox1r and Ox2r orexin receptors contribute to the cardiovascular and locomotor components of the novelty stress response in the rat. Neuropharmacology 2015;89:146-56. [PMID: 25239810 DOI: 10.1016/j.neuropharm.2014.09.012] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
85 Oh J, Petersen C, Walsh CM, Bittencourt JC, Neylan TC, Grinberg LT. The role of co-neurotransmitters in sleep and wake regulation. Mol Psychiatry 2019;24:1284-95. [PMID: 30377299 DOI: 10.1038/s41380-018-0291-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
86 Krystal AD. New Developments in Insomnia Medications of Relevance to Mental Health Disorders. Psychiatr Clin North Am 2015;38:843-60. [PMID: 26600112 DOI: 10.1016/j.psc.2015.08.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
87 Yee KL, Mccrea J, Panebianco D, Liu W, Lewis N, Cabalu T, Ramael S, Wrishko RE. Safety, Tolerability, and Pharmacokinetics of Suvorexant: A Randomized Rising-Dose Trial in Healthy Men. Clin Drug Investig 2018;38:631-8. [DOI: 10.1007/s40261-018-0650-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
88 Alijanpour S, Tirgar F, Zarrindast MR. Role of dorsal hippocampal orexin-1 receptors in memory restoration induced by morphine sensitization phenomenon. Neuroscience 2016;312:215-26. [PMID: 26592714 DOI: 10.1016/j.neuroscience.2015.11.023] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
89 Kim AK, Brown RM, Lawrence AJ. The role of orexins/hypocretins in alcohol use and abuse: an appetitive-reward relationship. Front Behav Neurosci 2012;6:78. [PMID: 23189046 DOI: 10.3389/fnbeh.2012.00078] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
90 Markham A. Daridorexant: First Approval. Drugs 2022. [PMID: 35298826 DOI: 10.1007/s40265-022-01699-y] [Reference Citation Analysis]
91 Bian H, Huang L, Li B, Hu Q, Liang X, Tang J, Zhang JH. The arousal effect of hyperbaric oxygen through orexin/hypocretin an upregulation on ketamine/ethanol-induced unconsciousness in male rats. J Neurosci Res 2020;98:201-11. [PMID: 30895638 DOI: 10.1002/jnr.24414] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
92 Erichsen JM, Calva CB, Reagan LP, Fadel JR. Intranasal insulin and orexins to treat age-related cognitive decline. Physiol Behav 2021;234:113370. [PMID: 33621561 DOI: 10.1016/j.physbeh.2021.113370] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
93 Scott LJ. Lemborexant: First Approval. Drugs 2020;80:425-32. [PMID: 32096020 DOI: 10.1007/s40265-020-01276-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
94 Firouzabadi N, Navabzadeh N, Moghimi-Sarani E, Haghnegahdar M. Orexin/Hypocretin Type 2 Receptor (HCRTR2) Gene as a Candidate Gene in Sertraline-Associated Insomnia in Depressed Patients. Neuropsychiatr Dis Treat 2020;16:1121-8. [PMID: 32440126 DOI: 10.2147/NDT.S250141] [Reference Citation Analysis]
95 Mohammadi S, Dolatshahi M, Zare-shahabadi A, Rahmani F. Untangling narcolepsy and diabetes: Pathomechanisms with eyes on therapeutic options. Brain Research 2019;1718:212-22. [DOI: 10.1016/j.brainres.2019.04.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
96 Jäntti MH, Putula J, Turunen PM, Näsman J, Reijonen S, Lindqvist C, Kukkonen JP. Autocrine endocannabinoid signaling through CB1 receptors potentiates OX1 orexin receptor signaling. Mol Pharmacol 2013;83:621-32. [PMID: 23233488 DOI: 10.1124/mol.112.080523] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
97 Ioachimescu OC, El-Solh AA. Pharmacotherapy of insomnia. Expert Opin Pharmacother 2012;13:1243-60. [PMID: 22578014 DOI: 10.1517/14656566.2012.683860] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
98 Vitale RM, Iannotti FA, Schiano Moriello A, Tunisi L, Piscitelli F, Savopoulos R, Cristino L, De Petrocellis L, Amodeo P, Gray R, Di Marzo V. Identification and Characterization of Cannabidiol as an OX1R Antagonist by Computational and In Vitro Functional Validation. Biomolecules 2021;11:1134. [PMID: 34439801 DOI: 10.3390/biom11081134] [Reference Citation Analysis]
99 Civelli O, Reinscheid RK, Zhang Y, Wang Z, Fredriksson R, Schiöth HB. G protein-coupled receptor deorphanizations. Annu Rev Pharmacol Toxicol 2013;53:127-46. [PMID: 23020293 DOI: 10.1146/annurev-pharmtox-010611-134548] [Cited by in Crossref: 111] [Cited by in F6Publishing: 113] [Article Influence: 11.1] [Reference Citation Analysis]
100 Matzeu A, Martin-Fardon R. Targeting the Orexin System for Prescription Opioid Use Disorder. Brain Sci 2020;10:E226. [PMID: 32290110 DOI: 10.3390/brainsci10040226] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
101 Malhotra S, Kushida CA. Primary hypersomnias of central origin. Continuum (Minneap Minn) 2013;19:67-85. [PMID: 23385695 DOI: 10.1212/01.CON.0000427212.05930.c4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
102 Li T, Xu W, Ouyang J, Lu X, Sherchan P, Lenahan C, Irio G, Zhang JH, Zhao J, Zhang Y, Tang J. Orexin A alleviates neuroinflammation via OXR2/CaMKKβ/AMPK signaling pathway after ICH in mice. J Neuroinflammation 2020;17:187. [PMID: 32539736 DOI: 10.1186/s12974-020-01841-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
103 Cai X, Wang H, Wang M, Wang D, Zhang Z, Wei R, Gao X, Zhang R, Wang C, Chen J. A novel phosphorylation site on orexin receptor 1 regulating orexinA-induced GRK2-biased signaling. Cell Signal 2020;75:109743. [PMID: 32827691 DOI: 10.1016/j.cellsig.2020.109743] [Reference Citation Analysis]
104 Uemura N, McCrea J, Sun H, Donikyan M, Zammit G, Liu R, Louridas B, Marsilio S, Lines C, Troyer MD, Wagner J. Effects of the orexin receptor antagonist suvorexant on respiration during sleep in healthy subjects. J Clin Pharmacol 2015;55:1093-100. [PMID: 25903940 DOI: 10.1002/jcph.523] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
105 Chase MH. A unified survival theory of the functioning of the hypocretinergic system. J Appl Physiol (1985) 2013;115:954-71. [PMID: 23640599 DOI: 10.1152/japplphysiol.00700.2012] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
106 Beig MI, Horiuchi J, Dampney RA, Carrive P. Both Ox1R and Ox2R orexin receptors contribute to the cardiorespiratory response evoked from the perifornical hypothalamus. Clin Exp Pharmacol Physiol 2015;42:1059-67. [DOI: 10.1111/1440-1681.12461] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
107 Matzeu A, Martin-fardon R. Understanding the Role of Orexin Neuropeptides in Drug Addiction: Preclinical Studies and Translational Value. Front Behav Neurosci 2022;15:787595. [DOI: 10.3389/fnbeh.2021.787595] [Reference Citation Analysis]
108 Wang C, Wang Q, Ji B, Pan Y, Xu C, Cheng B, Bai B, Chen J. The Orexin/Receptor System: Molecular Mechanism and Therapeutic Potential for Neurological Diseases. Front Mol Neurosci 2018;11:220. [PMID: 30002617 DOI: 10.3389/fnmol.2018.00220] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 13.8] [Reference Citation Analysis]
109 Liu X, Yang R, Bai W, Xu X, Bi F, Zhu M, Dou X, Li H. Exploring the role of orexin B-sirtuin 1-HIF-1α in diabetes-mellitus induced vascular endothelial dysfunction and associated myocardial injury in rats. Life Sci 2020;254:117041. [PMID: 31715188 DOI: 10.1016/j.lfs.2019.117041] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
110 Murphy P, Moline M, Mayleben D, Rosenberg R, Zammit G, Pinner K, Dhadda S, Hong Q, Giorgi L, Satlin A. Lemborexant, A Dual Orexin Receptor Antagonist (DORA) for the Treatment of Insomnia Disorder: Results From a Bayesian, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study. J Clin Sleep Med 2017;13:1289-99. [PMID: 29065953 DOI: 10.5664/jcsm.6800] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 10.0] [Reference Citation Analysis]
111 Coleman PJ, Schreier JD, Cox CD, Breslin MJ, Whitman DB, Bogusky MJ, Mcgaughey GB, Bednar RA, Lemaire W, Doran SM, Fox SV, Garson SL, Gotter AL, Harrell CM, Reiss DR, Cabalu TD, Cui D, Prueksaritanont T, Stevens J, Tannenbaum PL, Ball RG, Stellabott J, Young SD, Hartman GD, Winrow CJ, Renger JJ. Discovery of [(2 R ,5 R )-5-{[(5-Fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone (MK-6096): A Dual Orexin Receptor Antagonist with Potent Sleep-Promoting Properties. ChemMedChem 2012;7:415-24. [DOI: 10.1002/cmdc.201200025] [Cited by in Crossref: 82] [Cited by in F6Publishing: 79] [Article Influence: 8.2] [Reference Citation Analysis]
112 Putula J, Kukkonen JP. Mapping of the binding sites for the OX1 orexin receptor antagonist, SB-334867, using orexin/hypocretin receptor chimaeras. Neuroscience Letters 2012;506:111-5. [DOI: 10.1016/j.neulet.2011.10.061] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
113 Borsook D, Maleki N, Becerra L, McEwen B. Understanding migraine through the lens of maladaptive stress responses: a model disease of allostatic load. Neuron. 2012;73:219-234. [PMID: 22284178 DOI: 10.1016/j.neuron.2012.01.001] [Cited by in Crossref: 195] [Cited by in F6Publishing: 183] [Article Influence: 19.5] [Reference Citation Analysis]
114 Roecker AJ, Reger TS, Mattern MC, Mercer SP, Bergman JM, Schreier JD, Cube RV, Cox CD, Li D, Lemaire W, Bruno JG, Harrell CM, Garson SL, Gotter AL, Fox SV, Stevens J, Tannenbaum PL, Prueksaritanont T, Cabalu TD, Cui D, Stellabott J, Hartman GD, Young SD, Winrow CJ, Renger JJ, Coleman PJ. Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia. Bioorg Med Chem Lett 2014;24:4884-90. [PMID: 25248679 DOI: 10.1016/j.bmcl.2014.08.041] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
115 Carrive P. Orexin, orexin receptor antagonists and central cardiovascular control. Front Neurosci 2013;7:257. [PMID: 24415993 DOI: 10.3389/fnins.2013.00257] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 3.8] [Reference Citation Analysis]
116 Baldascino E, Di Cristina G, Tedesco P, Hobbs C, Shaw TJ, Ponte G, Andrews PLR. The Gastric Ganglion of Octopus vulgaris: Preliminary Characterization of Gene- and Putative Neurochemical-Complexity, and the Effect of Aggregata octopiana Digestive Tract Infection on Gene Expression. Front Physiol 2017;8:1001. [PMID: 29326594 DOI: 10.3389/fphys.2017.01001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
117 Szabadi E. Selective targets for arousal-modifying drugs: implications for the treatment of sleep disorders. Drug Discovery Today 2014;19:701-8. [DOI: 10.1016/j.drudis.2014.01.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
118 de Martin Truzzi G, Naufel MF, Tufik S, Coelho FM. The influence of narcolepsy on olfactory function: a review. Sleep Med 2020;72:75-81. [PMID: 32554327 DOI: 10.1016/j.sleep.2020.03.023] [Reference Citation Analysis]
119 Matzeu A, Martin-Fardon R. Targeting the orexin system for prescription opioid use disorder: Orexin-1 receptor blockade prevents oxycodone taking and seeking in rats. Neuropharmacology 2020;164:107906. [PMID: 31841797 DOI: 10.1016/j.neuropharm.2019.107906] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
120 Suzuki R, Nozawa D, Futamura A, Nishikawa-shimono R, Abe M, Hattori N, Ohta H, Araki Y, Kambe D, Ohmichi M, Tokura S, Aoki T, Ohtake N, Kawamoto H. Discovery and in vitro and in vivo profiles of N-ethyl-N-[2-[3-(5-fluoro-2-pyridinyl)-1H-pyrazol-1-yl]ethyl]-2-(2H-1,2,3-triazol-2-yl)-benzamide as a novel class of dual orexin receptor antagonist. Bioorganic & Medicinal Chemistry 2015;23:1260-75. [DOI: 10.1016/j.bmc.2015.01.044] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
121 Ward RJ, Pediani JD, Milligan G. Heteromultimerization of cannabinoid CB(1) receptor and orexin OX(1) receptor generates a unique complex in which both protomers are regulated by orexin A. J Biol Chem 2011;286:37414-28. [PMID: 21908614 DOI: 10.1074/jbc.M111.287649] [Cited by in Crossref: 64] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
122 Kukkonen JP. Physiology of the orexinergic/hypocretinergic system: a revisit in 2012. Am J Physiol Cell Physiol 2013;304:C2-32. [PMID: 23034387 DOI: 10.1152/ajpcell.00227.2012] [Cited by in Crossref: 93] [Cited by in F6Publishing: 91] [Article Influence: 9.3] [Reference Citation Analysis]
123 Hopf FW. Recent perspectives on orexin/hypocretin promotion of addiction-related behaviors. Neuropharmacology 2020;168:108013. [PMID: 32092435 DOI: 10.1016/j.neuropharm.2020.108013] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
124 Gentile TA, Simmons SJ, Watson MN, Connelly KL, Brailoiu E, Zhang Y, Muschamp JW. Effects of Suvorexant, a Dual Orexin/Hypocretin Receptor Antagonist, on Impulsive Behavior Associated with Cocaine. Neuropsychopharmacology 2018;43:1001-9. [PMID: 28741623 DOI: 10.1038/npp.2017.158] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
125 Boutrel B, Steiner N, Halfon O. The hypocretins and the reward function: what have we learned so far? Front Behav Neurosci 2013;7:59. [PMID: 23781178 DOI: 10.3389/fnbeh.2013.00059] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
126 Sun H, Kennedy WP, Wilbraham D, Lewis N, Calder N, Li X, Ma J, Yee KL, Ermlich S, Mangin E, Lines C, Rosen L, Chodakewitz J, Murphy GM. Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men. Sleep 2013;36:259-67. [PMID: 23372274 DOI: 10.5665/sleep.2386] [Cited by in Crossref: 11] [Cited by in F6Publishing: 48] [Article Influence: 1.2] [Reference Citation Analysis]
127 Matzeu A, Martin-Fardon R. Drug Seeking and Relapse: New Evidence of a Role for Orexin and Dynorphin Co-transmission in the Paraventricular Nucleus of the Thalamus. Front Neurol 2018;9:720. [PMID: 30210441 DOI: 10.3389/fneur.2018.00720] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
128 Shoblock JR, Welty N, Aluisio L, Fraser I, Motley ST, Morton K, Palmer J, Bonaventure P, Carruthers NI, Lovenberg TW, Boggs J, Galici R. Selective blockade of the orexin-2 receptor attenuates ethanol self-administration, place preference, and reinstatement. Psychopharmacology 2011;215:191-203. [DOI: 10.1007/s00213-010-2127-x] [Cited by in Crossref: 99] [Cited by in F6Publishing: 102] [Article Influence: 8.3] [Reference Citation Analysis]
129 Vaseghi S, Zarrabian S, Haghparast A. Reviewing the role of the orexinergic system and stressors in modulating mood and reward-related behaviors. Neurosci Biobehav Rev 2021;133:104516. [PMID: 34973302 DOI: 10.1016/j.neubiorev.2021.104516] [Reference Citation Analysis]
130 Turunen PM, Jäntti MH, Kukkonen JP. OX1 orexin/hypocretin receptor signaling through arachidonic acid and endocannabinoid release. Mol Pharmacol 2012;82:156-67. [PMID: 22550093 DOI: 10.1124/mol.112.078063] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 4.1] [Reference Citation Analysis]
131 Tang H, Zhu Q, Li W, Qin S, Gong Y, Wang H, Shioda S, Li S, Huang J, Liu B, Fang Y, Liu Y, Wang S, Guo Y, Xia Q, Guo Y, Xu Z. Neurophysiology and Treatment of Disorders of Consciousness Induced by Traumatic Brain Injury: Orexin Signaling as a Potential Therapeutic Target. Curr Pharm Des 2019;25:4208-20. [PMID: 31663471 DOI: 10.2174/1381612825666191029101830] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
132 Christopher JA. Orexin receptor antagonists. Pharm Pat Anal 2012;1:329-46. [PMID: 24236845 DOI: 10.4155/ppa.12.27] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
133 Tannenbaum PL, Tye SJ, Stevens J, Gotter AL, Fox SV, Savitz AT, Coleman PJ, Uslaner JM, Kuduk SD, Hargreaves R, Winrow CJ, Renger JJ. Inhibition of Orexin Signaling Promotes Sleep Yet Preserves Salient Arousability in Monkeys. Sleep 2016;39:603-12. [PMID: 26943466 DOI: 10.5665/sleep.5536] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
134 Mieda M, Tsujino N, Sakurai T. Differential roles of orexin receptors in the regulation of sleep/wakefulness. Front Endocrinol (Lausanne) 2013;4:57. [PMID: 23730297 DOI: 10.3389/fendo.2013.00057] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
135 Perrey DA, Gilmour BP, Runyon SP, Thomas BF, Zhang Y. Diaryl urea analogues of SB-334867 as orexin-1 receptor antagonists. Bioorg Med Chem Lett 2011;21:2980-5. [PMID: 21478014 DOI: 10.1016/j.bmcl.2011.03.048] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
136 Zheng Y, Stiles L, Chien YT, Darlington CL, Smith PF. The effects of acute stress-induced sleep disturbance on acoustic trauma-induced tinnitus in rats. Biomed Res Int 2014;2014:724195. [PMID: 25162023 DOI: 10.1155/2014/724195] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
137 Mieda M, Sakurai T. Orexin (hypocretin) receptor agonists and antagonists for treatment of sleep disorders. Rationale for development and current status. CNS Drugs 2013;27:83-90. [PMID: 23359095 DOI: 10.1007/s40263-012-0036-8] [Cited by in Crossref: 62] [Cited by in F6Publishing: 62] [Article Influence: 6.9] [Reference Citation Analysis]
138 Colas D, Manca A, Delcroix JD, Mourrain P. Orexin A and orexin receptor 1 axonal traffic in dorsal roots at the CNS/PNS interface. Front Neurosci 2014;8:20. [PMID: 24574957 DOI: 10.3389/fnins.2014.00020] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
139 Dubey AK, Handu SS, Mediratta PK. Suvorexant: The first orexin receptor antagonist to treat insomnia. J Pharmacol Pharmacother 2015;6:118-21. [PMID: 25969666 DOI: 10.4103/0976-500X.155496] [Cited by in Crossref: 36] [Cited by in F6Publishing: 10] [Article Influence: 5.1] [Reference Citation Analysis]
140 Damasio A, Carvalho GB. The nature of feelings: evolutionary and neurobiological origins. Nat Rev Neurosci 2013;14:143-52. [PMID: 23329161 DOI: 10.1038/nrn3403] [Cited by in Crossref: 491] [Cited by in F6Publishing: 340] [Article Influence: 54.6] [Reference Citation Analysis]
141 Perrey DA, Zhang Y. Therapeutics development for addiction: Orexin-1 receptor antagonists. Brain Res 2020;1731:145922. [PMID: 30148984 DOI: 10.1016/j.brainres.2018.08.025] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
142 Hayward LF, Hampton EE, Ferreira LF, Christou DD, Yoo J, Hernandez ME, Martin EJ. Chronic heart failure alters orexin and melanin concentrating hormone but not corticotrophin releasing hormone-related gene expression in the brain of male Lewis rats. Neuropeptides 2015;52:67-72. [DOI: 10.1016/j.npep.2015.06.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
143 Gamble MC, Katsuki F, Mccoy JG, Strecker RE, Mckenna JT. The dual orexinergic receptor antagonist DORA-22 improves the sleep disruption and memory impairment produced by a rodent insomnia model. Sleep 2019. [DOI: 10.1093/sleep/zsz241] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
144 Alexandre C, Andermann ML, Scammell TE. Control of arousal by the orexin neurons. Curr Opin Neurobiol 2013;23:752-9. [PMID: 23683477 DOI: 10.1016/j.conb.2013.04.008] [Cited by in Crossref: 72] [Cited by in F6Publishing: 74] [Article Influence: 8.0] [Reference Citation Analysis]
145 Zheng C, Deng QQ, Liu LL, Wang MY, Zhang G, Sheng WL, Weng SJ, Yang XL, Zhong YM. Orexin-A differentially modulates AMPA-preferring responses of ganglion cells and amacrine cells in rat retina. Neuropharmacology 2015;93:80-93. [PMID: 25656479 DOI: 10.1016/j.neuropharm.2015.01.016] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
146 Matzeu A, Zamora-Martinez ER, Martin-Fardon R. The paraventricular nucleus of the thalamus is recruited by both natural rewards and drugs of abuse: recent evidence of a pivotal role for orexin/hypocretin signaling in this thalamic nucleus in drug-seeking behavior. Front Behav Neurosci 2014;8:117. [PMID: 24765071 DOI: 10.3389/fnbeh.2014.00117] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 6.1] [Reference Citation Analysis]
147 Ghazal P, Corsi M, Roth A, Faggioni F, Corti C, Merlo Pick E, Pucciarelli S, Ciccocioppo R, Ubaldi M. Paradoxical response to the sedative effects of diazepam and alcohol in C57BL/6J mice lacking the neuropeptide S receptor. Peptides 2014;61:107-13. [PMID: 25240770 DOI: 10.1016/j.peptides.2014.09.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
148 Xu T, Yang Y, Ward R, Gao L, Liu Y. Orexin receptors: Multi-functional therapeutic targets for sleeping disorders, eating disorders, drug addiction, cancers and other physiological disorders. Cellular Signalling 2013;25:2413-23. [DOI: 10.1016/j.cellsig.2013.07.025] [Cited by in Crossref: 68] [Cited by in F6Publishing: 65] [Article Influence: 7.6] [Reference Citation Analysis]
149 Biswabharati S, Jean-Xavier C, Eaton SEA, Lognon AP, Brett R, Hardjasa L, Whelan PJ. Orexinergic Modulation of Spinal Motor Activity in the Neonatal Mouse Spinal Cord. eNeuro 2018;5:ENEURO. [PMID: 30417080 DOI: 10.1523/ENEURO.0226-18.2018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
150 Qiao SN, Zhou W, Liu LL, Zhang DQ, Zhong YM. Orexin-A Suppresses Signal Transmission to Dopaminergic Amacrine Cells From Outer and Inner Retinal Photoreceptors. Invest Ophthalmol Vis Sci 2017;58:4712-21. [PMID: 28910447 DOI: 10.1167/iovs.17-21835] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
151 Gemici B, Tan R, Birsen İ, İzgüt Uysal VN. Gastroprotective effect of orexin-A and heme oxygenase system. Journal of Surgical Research 2015;193:626-33. [DOI: 10.1016/j.jss.2014.08.048] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
152 Karhu L, Turku A, Xhaard H. Modeling of the OX1R-orexin-A complex suggests two alternative binding modes. BMC Struct Biol 2015;15:9. [PMID: 25957175 DOI: 10.1186/s12900-015-0036-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
153 German NA, Decker AM, Gilmour BP, Thomas BF, Zhang Y. Truncated Orexin Peptides: Structure-Activity Relationship Studies. ACS Med Chem Lett 2013;4:1224-7. [PMID: 24707347 DOI: 10.1021/ml400333a] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
154 Nepovimova E, Janockova J, Misik J, Kubik S, Stuchlik A, Vales K, Korabecny J, Mezeiova E, Dolezal R, Soukup O, Kobrlova T, Pham NL, Nguyen TD, Konecny J, Kuca K. Orexin supplementation in narcolepsy treatment: A review. Med Res Rev 2019;39:961-75. [PMID: 30426515 DOI: 10.1002/med.21550] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
155 Wang W, Li Q, Pan Y, Zhu D, Wang L. Influence of hypercapnia on the synthesis of neuropeptides and their receptors in murine brain. Respirology 2013;18:102-7. [PMID: 22882587 DOI: 10.1111/j.1440-1843.2012.02245.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
156 Liu F, Weng SJ, Yang XL, Zhong YM. Orexin-A potentiates L-type calcium/barium currents in rat retinal ganglion cells. Neuroscience 2015;305:225-37. [PMID: 26259903 DOI: 10.1016/j.neuroscience.2015.08.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
157 Cruz HG, Hoever P, Chakraborty B, Schoedel K, Sellers EM, Dingemanse J. Assessment of the Abuse Liability of a Dual Orexin Receptor Antagonist: A Crossover Study of Almorexant and Zolpidem in Recreational Drug Users. CNS Drugs 2014;28:361-72. [DOI: 10.1007/s40263-014-0150-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
158 Buczek L, Migliaccio J, Petrovich GD. Hedonic Eating: Sex Differences and Characterization of Orexin Activation and Signaling. Neuroscience 2020;436:34-45. [PMID: 32283183 DOI: 10.1016/j.neuroscience.2020.04.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
159 Kim JS, Martin-Fardon R. Possible Role of CRF-Hcrt Interaction in the Infralimbic Cortex in the Emergence and Maintenance of Compulsive Alcohol-Seeking Behavior. Alcohol Clin Exp Res 2020;44:354-67. [PMID: 31840823 DOI: 10.1111/acer.14264] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
160 Chieffi S, Messina G, Villano I, Messina A, Valenzano A, Moscatelli F, Salerno M, Sullo A, Avola R, Monda V, Cibelli G, Monda M. Neuroprotective Effects of Physical Activity: Evidence from Human and Animal Studies. Front Neurol 2017;8:188. [PMID: 28588546 DOI: 10.3389/fneur.2017.00188] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 8.6] [Reference Citation Analysis]
161 Murphy KR, Deshpande SA, Yurgel ME, Quinn JP, Weissbach JL, Keene AC, Dawson-Scully K, Huber R, Tomchik SM, Ja WW. Postprandial sleep mechanics in Drosophila. Elife 2016;5:e19334. [PMID: 27873574 DOI: 10.7554/eLife.19334] [Cited by in Crossref: 46] [Cited by in F6Publishing: 29] [Article Influence: 7.7] [Reference Citation Analysis]
162 Chung JYL, Zhong Y, Maloney KM, Reamer RA, Moore JC, Strotman H, Kalinin A, Feng R, Strotman NA, Xiang B, Yasuda N. Unusual Pyrimidine Participation: Efficient Stereoselective Synthesis of Potent Dual Orexin Receptor Antagonist MK-6096. Org Lett 2014;16:5890-3. [DOI: 10.1021/ol5028249] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
163 Ellenbogen JM, Pace-Schott EF. Drug-induced sleep: theoretical and practical considerations. Pflugers Arch 2012;463:177-86. [PMID: 21953011 DOI: 10.1007/s00424-011-1033-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
164 Baimel C, Borgland SL, Corrigall W. Cocaine and Nicotine Research Illustrates a Range of Hypocretin Mechanisms in Addiction. Sleep Hormones. Elsevier; 2012. pp. 291-313. [DOI: 10.1016/b978-0-12-394623-2.00016-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
165 Sun H, Palcza J, Card D, Gipson A, Rosenberg R, Kryger M, Lines C, Wagner JA, Troyer MD. Effects of Suvorexant, an Orexin Receptor Antagonist, on Respiration during Sleep In Patients with Obstructive Sleep Apnea. J Clin Sleep Med 2016;12:9-17. [PMID: 26194728 DOI: 10.5664/jcsm.5382] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 4.6] [Reference Citation Analysis]
166 Risco S, Mediavilla C. Orexin-1 receptor antagonist in central nucleus of the amygdala attenuates the acquisition of flavor-taste preference in rats. Pharmacol Biochem Behav 2014;126:7-12. [PMID: 25223979 DOI: 10.1016/j.pbb.2014.09.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
167 Roecker AJ, Mercer SP, Harrell CM, Garson SL, Fox SV, Gotter AL, Prueksaritanont T, Cabalu TD, Cui D, Lemaire W, Winrow CJ, Renger JJ, Coleman PJ. Discovery of dual orexin receptor antagonists with rat sleep efficacy enabled by expansion of the acetonitrile-assisted/diphosgene-mediated 2,4-dichloropyrimidine synthesis. Bioorganic & Medicinal Chemistry Letters 2014;24:2079-85. [DOI: 10.1016/j.bmcl.2014.03.052] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
168 Zhou L, Sun WL, See RE. Orexin Receptor Targets for Anti-Relapse Medication Development in Drug Addiction. Pharmaceuticals (Basel) 2011;4:804-21. [PMID: 23997653 DOI: 10.3390/ph4060804] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
169 Gotter AL, Roecker AJ, Hargreaves R, Coleman PJ, Winrow CJ, Renger JJ. Orexin receptors as therapeutic drug targets. Prog Brain Res 2012;198:163-88. [PMID: 22813974 DOI: 10.1016/B978-0-444-59489-1.00010-0] [Cited by in Crossref: 71] [Cited by in F6Publishing: 24] [Article Influence: 7.1] [Reference Citation Analysis]
170 Vermeeren A, Jongen S, Murphy P, Moline M, Filippov G, Pinner K, Perdomo C, Landry I, Majid O, Van Oers ACM, Van Leeuwen CJ, Ramaekers JG, Vuurman EFPM. On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers. Sleep 2019;42:zsy260. [PMID: 30597112 DOI: 10.1093/sleep/zsy260] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 12.0] [Reference Citation Analysis]
171 Mohammad-pour Kargar H, Azizi H, Mirnajafi-zadeh J, Ali Reza M, Semnanian S. Microinjection of orexin-A into the rat locus coeruleus nucleus induces analgesia via cannabinoid type-1 receptors. Brain Research 2015;1624:424-32. [DOI: 10.1016/j.brainres.2015.07.050] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
172 Chen Y, Guo Y, Yan X, Zeng M, Chen H, Qiu D, Wang J. Orexin-A Excites Airway Vagal Preganglionic Neurons via Activation of Orexin Receptor Type 1 and Type 2 in Rats. Front Cell Neurosci 2019;13:478. [PMID: 31708749 DOI: 10.3389/fncel.2019.00478] [Reference Citation Analysis]
173 Winrow CJ, Gotter AL, Cox CD, Tannenbaum PL, Garson SL, Doran SM, Breslin MJ, Schreier JD, Fox SV, Harrell CM, Stevens J, Reiss DR, Cui D, Coleman PJ, Renger JJ. Pharmacological characterization of MK-6096 – A dual orexin receptor antagonist for insomnia. Neuropharmacology 2012;62:978-87. [DOI: 10.1016/j.neuropharm.2011.10.003] [Cited by in Crossref: 91] [Cited by in F6Publishing: 91] [Article Influence: 9.1] [Reference Citation Analysis]
174 Plaza-Zabala A, Maldonado R, Berrendero F. The hypocretin/orexin system: implications for drug reward and relapse. Mol Neurobiol 2012;45:424-39. [PMID: 22430644 DOI: 10.1007/s12035-012-8255-z] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 3.5] [Reference Citation Analysis]
175 Saper CB, Scammell TE. Emerging therapeutics in sleep: Emerging Therapeutics in Sleep. Ann Neurol 2013;74:435-40. [DOI: 10.1002/ana.24000] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
176 Singh IP, Shah P. Tetrahydroisoquinolines in therapeutics: a patent review (2010-2015). Expert Opin Ther Pat 2017;27:17-36. [PMID: 27623022 DOI: 10.1080/13543776.2017.1236084] [Cited by in Crossref: 49] [Cited by in F6Publishing: 31] [Article Influence: 8.2] [Reference Citation Analysis]
177 Herring WJ, Roth T, Krystal AD, Michelson D. Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications. J Sleep Res 2018;28. [DOI: 10.1111/jsr.12782] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
178 Chieffi S, Messina G, Villano I, Messina A, Esposito M, Monda V, Valenzano A, Moscatelli F, Esposito T, Carotenuto M, Viggiano A, Cibelli G, Monda M. Exercise Influence on Hippocampal Function: Possible Involvement of Orexin-A. Front Physiol 2017;8:85. [PMID: 28261108 DOI: 10.3389/fphys.2017.00085] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
179 Ufer M, Kelsh D, Schoedel KA, Dingemanse J. Abuse potential assessment of the new dual orexin receptor antagonist daridorexant in recreational sedative drug users as compared to suvorexant and zolpidem. Sleep 2021:zsab224. [PMID: 34480579 DOI: 10.1093/sleep/zsab224] [Reference Citation Analysis]
180 Karhu L, Magarkar A, Bunker A, Xhaard H. Determinants of Orexin Receptor Binding and Activation-A Molecular Dynamics Study. J Phys Chem B 2019;123:2609-22. [PMID: 30786708 DOI: 10.1021/acs.jpcb.8b10220] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
181 Karhu L, Weisell J, Turunen PM, Leino TO, Pätsi H, Xhaard H, Kukkonen JP, Wallén EAA. Stapled truncated orexin peptides as orexin receptor agonists. Peptides 2018;102:54-60. [PMID: 29475074 DOI: 10.1016/j.peptides.2018.02.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
182 Hagar JM, Macht VA, Wilson SP, Fadel JR. Upregulation of orexin/hypocretin expression in aged rats: Effects on feeding latency and neurotransmission in the insular cortex. Neuroscience 2017;350:124-32. [PMID: 28344067 DOI: 10.1016/j.neuroscience.2017.03.021] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
183 De Boer P, Drevets WC, Rofael H, van der Ark P, Kent JM, Kezic I, Parapatics S, Dorffner G, van Gerven J, Beneš H, Keicher C, Jahn H, Seiden DJ, Luthringer R. A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity. J Psychopharmacol 2018;32:668-77. [PMID: 29848147 DOI: 10.1177/0269881118773745] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
184 Saad L, Sartori M, Pol Bodetto S, Romieu P, Kalsbeek A, Zwiller J, Anglard P. Regulation of Brain DNA Methylation Factors and of the Orexinergic System by Cocaine and Food Self-Administration. Mol Neurobiol 2019;56:5315-31. [DOI: 10.1007/s12035-018-1453-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
185 Keefer SE, Cole S, Petrovich GD. Orexin/hypocretin receptor 1 signaling mediates Pavlovian cue-food conditioning and extinction. Physiol Behav 2016;162:27-36. [PMID: 26945612 DOI: 10.1016/j.physbeh.2016.02.042] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
186 Flick AC, Leverett CA, Ding HX, McInturff E, Fink SJ, Mahapatra S, Carney DW, Lindsey EA, DeForest JC, France SP, Berritt S, Bigi-Botterill SV, Gibson TS, Liu Y, O'Donnell CJ. Synthetic Approaches to the New Drugs Approved during 2019. J Med Chem 2021;64:3604-57. [PMID: 33783211 DOI: 10.1021/acs.jmedchem.1c00208] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
187 Mieda M. The roles of orexins in sleep/wake regulation. Neuroscience Research 2017;118:56-65. [DOI: 10.1016/j.neures.2017.03.015] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 8.4] [Reference Citation Analysis]
188 Tavakkolifard M, Vousooghi N, Mahboubi S, Golab F, Ejtemaei Mehr S, Zarrindast MR. Evaluation of the relationship between the gene expression level of orexin-1 receptor in the rat blood and prefrontal cortex, novelty-seeking, and proneness to methamphetamine dependence: A candidate biomarker. Peptides 2020;131:170368. [PMID: 32668268 DOI: 10.1016/j.peptides.2020.170368] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
189 Liu JJ, Mirabella VR, Pang ZP. Cell type- and pathway-specific synaptic regulation of orexin neurocircuitry. Brain Res 2020;1731:145974. [PMID: 30296428 DOI: 10.1016/j.brainres.2018.10.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
190 Roecker AJ, Cox CD, Coleman PJ. Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia. J Med Chem 2016;59:504-30. [PMID: 26317591 DOI: 10.1021/acs.jmedchem.5b00832] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 8.9] [Reference Citation Analysis]
191 Barson JR. Orexin/hypocretin and dysregulated eating: Promotion of foraging behavior. Brain Res 2020;1731:145915. [PMID: 30125533 DOI: 10.1016/j.brainres.2018.08.018] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
192 Lebold TP, Bonaventure P, Shireman BT. Selective orexin receptor antagonists. Bioorg Med Chem Lett 2013;23:4761-9. [PMID: 23891187 DOI: 10.1016/j.bmcl.2013.06.057] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 5.9] [Reference Citation Analysis]
193 Holden JE. Putting the bio in biobehavioral: animal models. West J Nurs Res 2011;33:1017-29. [PMID: 21454886 DOI: 10.1177/0193945911403776] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
194 Czora-poczwardowska K, Kujawski R, Słyńko-krzyżostaniak J, Mikołajczak PŁ, Szulc M. Orexin receptor blockers: A tool for lowering alcohol intake and alcohol addictive behavior in the light of preclinical studies. Postępy Higieny i Medycyny Doświadczalnej 2021;75:959-69. [DOI: 10.2478/ahem-2021-0007] [Reference Citation Analysis]
195 Gotter AL, Webber AL, Coleman PJ, Renger JJ, Winrow CJ. International Union of Basic and Clinical Pharmacology. LXXXVI. Orexin Receptor Function, Nomenclature and Pharmacology. Pharmacol Rev 2012;64:389-420. [DOI: 10.1124/pr.111.005546] [Cited by in Crossref: 114] [Cited by in F6Publishing: 107] [Article Influence: 11.4] [Reference Citation Analysis]
196 Roecker AJ, Mercer SP, Bergman JM, Gilbert KF, Kuduk SD, Harrell CM, Garson SL, Fox SV, Gotter AL, Tannenbaum PL, Prueksaritanont T, Cabalu TD, Cui D, Lemaire W, Winrow CJ, Renger JJ, Coleman PJ. Discovery of diazepane amide DORAs and 2-SORAs enabled by exploration of isosteric quinazoline replacements. Bioorganic & Medicinal Chemistry Letters 2015;25:4992-9. [DOI: 10.1016/j.bmcl.2014.12.081] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
197 Carrive P, Kuwaki T. Orexin and Central Modulation of Cardiovascular and Respiratory Function. In: Lawrence AJ, de Lecea L, editors. Behavioral Neuroscience of Orexin/Hypocretin. Cham: Springer International Publishing; 2017. pp. 157-96. [DOI: 10.1007/7854_2016_46] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
198 Sachidanandan D, Reddy HP, Mani A, Hyde GJ, Bera AK. The Neuropeptide Orexin-A Inhibits the GABAA Receptor by PKC and Ca2+/CaMKII-Dependent Phosphorylation of Its β1 Subunit. J Mol Neurosci 2017;61:459-67. [DOI: 10.1007/s12031-017-0886-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
199 Turku A, Rinne MK, Boije Af Gennäs G, Xhaard H, Lindholm D, Kukkonen JP. Orexin receptor agonist Yan 7874 is a weak agonist of orexin/hypocretin receptors and shows orexin receptor-independent cytotoxicity. PLoS One 2017;12:e0178526. [PMID: 28575023 DOI: 10.1371/journal.pone.0178526] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
200 Elliott JE, De Luche SE, Churchill MJ, Moore C, Cohen AS, Meshul CK, Lim MM. Dietary therapy restores glutamatergic input to orexin/hypocretin neurons after traumatic brain injury in mice. Sleep 2018;41. [PMID: 29315422 DOI: 10.1093/sleep/zsx212] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
201 Shakeri-Nejad K, Hoch M, Hoever P, Dingemanse J. Influence of mild and moderate liver impairment on the pharmacokinetics and metabolism of almorexant, a dual orexin receptor antagonist. Eur J Pharm Sci 2013;49:836-44. [PMID: 23770377 DOI: 10.1016/j.ejps.2013.06.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
202 Kumar S, Behl T, Sehgal A, Singh S, Sharma N, Bhatia S, Al-Harassi A, Abdel-Daim MM, Bungau S. Exploring the Role of Orexinergic Neurons in Parkinson's Disease. Neurotox Res 2021. [PMID: 34495449 DOI: 10.1007/s12640-021-00411-4] [Reference Citation Analysis]